Adalimumab (Anti-Human TNF-alpha, Human Antibody) |
| Catalog No.GC34214 |
Adalimumab (Anti-Human TNF-alpha, Human Antibody) is a human monoclonal IgG1 antibody targeting tumour necrosis factorα (TNF-α).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 331731-18-1
Sample solution is provided at 25 µL, 10mM.
Adalimumab (Anti-Human TNF-alpha, Human Antibody) is one of the leading therapies for the treatment of rheumatoid arthritis. It is a humanized monoclonal antibody that binds to TNF-α and blocks its interaction with the TNF receptor [1]. It neutralizes both soluble as well as transmembrane TNF-α[2].
Adalimumab (Anti-Human TNF-alpha, Human Antibody) prevents major inflammatory effects of TNF-α on endothelial activation, endothelial monocyte adhesion, endothelial leakage[3].
Adalimumab (Anti-Human TNF-alpha, Human Antibody) prevented TNFα upregulation, reduced photoreceptor cell death, slowed microglial and MÜller cell activation, improved antioxidant response and ameliorated the energetic and metabolic dysfunction at P18[4]. VaD rats treated with Adalimumab (Anti-Human TNF-alpha, Human Antibody) exhibited significant improvements in memory. In addition, Adalimumab (Anti-Human TNF-alpha, Human Antibody) treatment significantly alleviated neuronal loss in the hippocampi of VaD rats[5]. The important role of TNF-α for atherosclerotic plaque development in experimental models is well documented, different TNF-α-deficient mice models consistently showed reduced plaque burden[6,7]. Adalimumab (Anti-Human TNF-alpha, Human Antibody) has demonstrated a good prognosis and improvement of physical function in rheumatoid arthritis [8].
References:
[1]. HÜrlimann D, Forster A, et,al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation. 2002 Oct 22;106(17):2184-7. doi: 10.1161/01.cir.0000037521.71373.44. PMID: 12390945.
[2]. Ternant D, Ducourau E, et,al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol. 2015 Feb;79(2):286-97. doi: 10.1111/bcp.12509. PMID: 25223394; PMCID: PMC4309634.
[3]. Oberoi R, Schuett J, et,al. Targeting Tumor Necrosis Factor-α with Adalimumab: Effects on Endothelial Activation and Monocyte Adhesion. PLoS One. 2016 Jul 28;11(7):e0160145. doi: 10.1371/journal.pone.0160145. PMID: 27467817; PMCID: PMC4965117.
[4]. MartÍnez-FernÁndez de la CÁmara C, HernÁndez-Pinto AM, et,al. Adalimumab Reduces Photoreceptor Cell Death in A Mouse Model of Retinal Degeneration. Sci Rep. 2015 Jul 14;5:11764. doi: 10.1038/srep11764. PMID: 26170250; PMCID: PMC4501000.
[5]. Xu JJ, Guo S, et,al. Adalimumab ameliorates memory impairments and neuroinflammation in chronic cerebral hypoperfusion rats. Aging (Albany NY). 2021 May 24;13(10):14001-14014. doi: 10.18632/aging.203009. Epub 2021 May 24. PMID: 34030135; PMCID: PMC8202885.
[6]. BrÅnÉn L, Hovgaard L, et,al. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):2137-42. doi: 10.1161/01.ATV.0000143933.20616.1b. Epub 2004 Sep 2. PMID: 15345516.
[7]. Ohta H, Wada H, et,al. Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis. 2005 May;180(1):11-7. doi: 10.1016/j.atherosclerosis.2004.11.016. Epub 2005 Jan 20. PMID: 15823270.
[8]. Toussirot E, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an update. Expert Opin Pharmacother. 2007 Sep;8(13):2089-107. doi: 10.1517/14656566.8.13.2089. PMID: 17714062.
Average Rating: 5 (Based on Reviews and 32 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *